Search Results - "Nguyen, Van T. M."
-
1
TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression
Published in Nature communications (10-05-2018)“…TGF-β/Activin induces epithelial-to-mesenchymal transition and stemness in pancreatic ductal adenocarcinoma (PDAC). However, the microRNAs (miRNAs) regulated…”
Get full text
Journal Article -
2
Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion
Published in Nature communications (27-11-2015)“…Endocrine therapies target the activation of the oestrogen receptor alpha (ERα) via distinct mechanisms, but it is not clear whether breast cancer cells can…”
Get full text
Journal Article -
3
Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression
Published in Nature communications (14-08-2019)“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text
Journal Article -
4
Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion
Published in Nature communications (06-08-2019)“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text
Journal Article -
5
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
Published in Nature (London) (09-10-2024)“…Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence . The predominant standard of care for…”
Get full text
Journal Article -
6
APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer
Published in Cell reports (Cambridge) (06-10-2015)“…Estrogen receptor α (ERα) is the key transcriptional driver in a large proportion of breast cancers. We report that APOBEC3B (A3B) is required for regulation…”
Get full text
Journal Article -
7
DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation
Published in Oncotarget (08-09-2015)“…The acquisition of endocrine therapy resistance in estrogen receptor α (ERα) breast cancer patients represents a major clinical problem. Notch signalling has…”
Get full text
Journal Article -
8
Induction of the TEAD Co-activator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer
Published in Cancer research (Chicago, Ill.) (02-10-2024)“…Resistance to endocrine therapies (ET) is common in estrogen receptor (ER) positive breast cancer, and most relapsed patients die with ET-resistant disease…”
Get full text
Journal Article -
9
The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer
Published in Oncotarget (08-09-2015)“…Over 30% of ERα breast cancer patients develop relapses and progress to metastatic disease despite treatment with endocrine therapies. The pioneer factor PBX1…”
Get full text
Journal Article -
10
Five-year follow-up of the iBerry Study: screening in early adolescence to identify those at risk of psychopathology in emerging adulthood
Published in European child & adolescent psychiatry (22-05-2024)“…The iBerry Study, a Dutch population-based high-risk cohort (n = 1022) examines the transition from subclinical symptoms to psychiatric disorders in…”
Get full text
Journal Article